Q2 Earnings Estimate for ITOS Issued By Leerink Partnrs

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of iTeos Therapeutics in a report released on Tuesday, July 22nd. Leerink Partnrs analyst D. Graybosch now anticipates that the company will earn ($1.28) per share for the quarter, down from their prior forecast of ($0.84). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($2.36) EPS and FY2025 earnings at ($4.43) EPS.

ITOS has been the subject of several other reports. Wells Fargo & Company restated an "equal weight" rating and issued a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Wedbush restated an "outperform" rating and issued a $10.50 price objective (down from $12.00) on shares of iTeos Therapeutics in a report on Monday, July 21st. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Piper Sandler lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, July 21st. Finally, Leerink Partners restated a "market perform" rating and issued a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $15.64.

iTeos Therapeutics Trading Up 0.2%

NASDAQ ITOS traded up $0.02 during trading on Thursday, hitting $10.17. The company had a trading volume of 1,048,505 shares, compared to its average volume of 1,411,017. iTeos Therapeutics has a one year low of $4.80 and a one year high of $18.13. The company has a market cap of $389.21 million, a price-to-earnings ratio of -3.35 and a beta of 1.49. The company's fifty day moving average is $9.88 and its 200-day moving average is $8.00.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14.

Institutional Trading of iTeos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ITOS. Strs Ohio bought a new stake in iTeos Therapeutics during the 1st quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics during the 4th quarter valued at about $42,000. CWM LLC increased its stake in iTeos Therapeutics by 428.7% during the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after purchasing an additional 6,936 shares in the last quarter. Paloma Partners Management Co bought a new stake in iTeos Therapeutics during the 1st quarter valued at about $65,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in iTeos Therapeutics during the 1st quarter valued at about $67,000. 97.16% of the stock is currently owned by institutional investors.

Insider Transactions at iTeos Therapeutics

In other iTeos Therapeutics news, Director David Hallal sold 38,228 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the sale, the insider owned 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,939,307 shares of company stock valued at $16,202,116 in the last three months. 12.50% of the stock is currently owned by company insiders.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.